30 January 2024 13:45Ziccum launches IR calendar for coming weeks
Ziccum has a schedule of coming IR activities, following the release of its Information Memorandum on 30 January which followed the announcement on 22 January of a new combined financial package that includes secured financing, a directed share issue...
30 January 2024 10:00Ziccum offentliggör informationsmemorandum med anledning av förestående företrädesemission av units
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER I NÅGON...
30 January 2024 10:00Ziccum publishes Information Memorandum in connection with the forthcoming rights issue of units
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER...
26 January 2024 08:30ZICCUM AB (publ) Year-End report Q4 2023
YEAR-END REPORT Q4 2023: 1 JANUARY – 31 DECEMBER 2023 Significant events during the Quarter Significant events after the Quarter CEO statementTaking Ziccum ahead towards new achievements, delivering milestones at a high pace2023 has been an amazing...
22 January 2024 22:22Ziccum säkrar finansiering till 2025 genom kombinerad riktad emission och företrädesemission för fortsatt genomförande av den ambitiösa affärsplanen.
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER I NÅGON...
22 January 2024 22:22Ziccum secures financing into 2025 through a combined directed share issue and rights issue to finance the continued execution of its ambitious business plan
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER...
10 January 2024 09:20Ziccum reports successful mRNA/LNP Feasibility Study with major Biotech Corporation
Ziccum and its Biotech Corporation collaboration partner have now reviewed the outcomes of the LaminarPace Feasibility study of mRNA/LNP materials, under the agreement signed on May 9th 2023. The study was very successful, and both parties confirm consistent...
21 December 2023 09:15VDs Julhälsning 2023: Ett avgörande år med betydande resultat
I slutet av ett spännande och händelserikt år, sammanfattar Ziccums VD Ann Gidner de milstolpar som uppnåtts och den gedigna strategiska planen för Ziccum som ligger till grund för resultaten, samt ser fram emot ett hektiskt...
21 December 2023 09:15CEO's Seasons Greetings 2023: A pivotal year of significant results
At the end of an exciting and eventful year, Ziccum CEO Ann Gidner summarizes the milestones reached, the robust Ziccum Strategic roadmap underpinning them and looks forward to a busy and dynamic 2024. Dear colleagues, partners, shareholders and friends...
4 December 2023 14:20Ziccum signs Academic Collaboration with University of Copenhagen on inhalable mRNA vaccine project
Ziccum AB (publ) has signed a Collaboration Agreement for a project jointly with the Department of Pharmacy, University of Copenhagen (UCPH), on the engineering of inhalable solid dosage forms of mRNA vaccines which will include in-vivo studies of mRNA/LNP...
1 December 2023 10:10Ziccum to present at ‘Inhaled Biologics’ live webinar with KOL Assoc Prof. Per Gerde
On Monday Dec 11 Ziccum presents as special guest at a live scientific webinar on ‘Inhaled Biologics’ with inhalation Key Opinion Leader Assoc. Prof. Per Gerde. New Ziccum COO Xavier Turon will present the company at the webinar, which addresses...
30 November 2023 14:00Ziccum AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ)
Ziccum today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ). Ziccum has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment...
28 November 2023 15:00Feasibility studies and continued revenue generation after third agreement signed with leading industry player: CEO Interview
Ziccum’s third funded Feasibility Study signed in recent months, announced on November 7, will provide further LaminarPace data and Ziccum revenues. CEO Ann Gidner discusses how the unique formulation and drying technology of Ziccum is being evaluated...
9 November 2023 09:15Ziccum launches News portal
Ziccum today launches a news portal - Ziccum Updates - on its website to share company news updates in a short, accessible format for investors, partners and followers.. The news posts will typically cover internal updates and initiatives, as well as...
8 November 2023 15:12Ziccum CEO Analyst video interview: new industry Agreement, Q3 highlights
Watch Ziccum CEO Ann Gidner in an exclusive new video interview with Eucaps analyst Jonathan Furelid. It provides insights and analysis of Ziccum’s new Evaluation Agreement, its third in six months, plus the company’s Q3 highlights. Watch...
7 November 2023 07:54Ziccum signs agreement for Vaccine Evaluation project with major US Biomanufacturing corporation
Ziccum AB (publ) (‘Ziccum’) has signed a Material Transfer and Evaluation Agreement for a Vaccine Evaluation project with one of the most important technology-focused Biomanufacturing corporations in the US. The project is funded and will...
27 October 2023 16:25Ziccums Q3-rapport – VD-uppdatering på svenska
Det tredje kvartalet 2023 har varit intensivt och produktivt för Ziccum - med det andra av två större utvärderingsavtal undertecknade, betydande intäkter genererade och extern validering av viktiga mRNA-data. Här delar VD...
25 October 2023 08:30ZICCUM AB (publ) Interim report Q3 2023
Significant events during the quarter Other events during the quarter Other events after the third quarter CEO statement Intensive data generation with world-leading Partners After kicking this quarter off with signing the second of two milestone agreements...
23 October 2023 08:30Ziccum reports positive results from external validation of mRNA activity after LaminarPace treatment
Ziccum AB (publ) has received data from external contract research (CRO) partner Truly Labs, confirming high activity levels in mRNA/LNP materials dried by LaminarPace, after continued internal confirmations. The in-vitro data validate the ability of...
5 September 2023 08:30Ziccum appoints senior biotech manager as new COO
Ziccum has appointed senior international biotech engineering manager Xavier Turon as its new Chief Operating Officer. Turon will lead the team developing LaminarPace, Ziccum’s unique mass transfer drying system, and is bringing extensive academic...